US · Healthcare · Medical Devices
EPS came in at 0.86 against a street estimate of 0.83 — a beat of 3.6%.
Analysts rate Boston Scientific Corp a strong buy (31 buy, 3 hold, 0 sell out of 34) with an average price target of $62.69.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.87% |
| Vanguard Capital Management, LLC | 6.49% |
| FMR Inc | 4.99% |
| State Street Corp | 4.57% |
| JPMorgan Chase & Co | 2.24% |
| Geode Capital Management, LLC | 2.24% |
| PRIMECAP Management Company | 2.19% |
| Vanguard Portfolio Management, LLC | 2.00% |
| Document | Date |
|---|---|
| Results announced · Q3 2026 | 2026-07-29 |
| Current report · Q3 2026 | 2026-07-27 |
| Company announcement · Q2 2026 | 2026-05-18 |
| Company announcement · Q2 2026 | 2026-05-18 |
| Quarterly report · Q1 2026 | 2026-05-01 |
| Proxy statement · Q1 2026 | 2026-03-18 |
| Annual report FY2025 | 2026-02-17 |
| Quarterly report · Q3 2025 | 2025-11-03 |
Readable in the app.
| Announcement | Date |
|---|---|
| Investment agreement with MiRus LLC for equity stake and acquisition option Boston Scientific announced a major investment in MiRus LLC, a private company developing cardiovascular and orthopedic medical devices. The deal structure includes: (1) Boston Scientific pa | 2026-05-18 |
| Accelerated share repurchase agreement for $2 billion announced Boston Scientific announced on May 18, 2026, that it entered into a $2 billion accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank. Under this program, the company will imm | 2026-05-18 |
| Entered into Agreement and Plan of Merger Boston Scientific announced it is acquiring Penumbra, Inc. for $374 per share in cash or 3.8721 Boston Scientific shares per Penumbra share (stockholder election). This is a material merger | 2026-01-15 |
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Boston Scientific Corp — free to start.
Google PlayApp StoreData updated 2026-08-05.